A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2
CONCLUSIONS: The study demonstrated the metabolic impact of switching from a DPP4i to a well-known SGLT2i, but further large-scale trials are needed to study the long-term effects of replacing a DPP4i with a SGLT2i. LIMITATIONS:Retrospective design, a short observation period, a small number of patients, no evaluations of the quality of life, side effects, or the cost, and data limited to only empagliflozin. CONFLICT OF INTEREST: No any relationship or support from the manufacturer of empagliflozin or other agents.
Source: Annals of Saudi Medicine - Category: General Medicine Tags: ISSUE 6 Source Type: research
More News: Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | General Medicine | Jardiance | Middle East Health | Saudi Arabia Health | Sodium | Study | Taiwan Health